Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Accumulated Expenses (2016 - 2025)

Corcept Therapeutics' Other Accumulated Expenses history spans 14 years, with the latest figure at $34.0 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses changed 0.25% to $34.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.0 million, a 0.25% change, with the full-year FY2025 number at $34.0 million, changed 0.25% from a year prior.
  • Other Accumulated Expenses hit $34.0 million in Q4 2025 for Corcept Therapeutics, up from $28.3 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CORT hit a ceiling of $34.0 million in Q4 2025 and a floor of $12.4 million in Q4 2021.
  • Historically, Other Accumulated Expenses has averaged $23.1 million across 5 years, with a median of $21.7 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: soared 58.78% in 2024 and later increased 0.25% in 2025.
  • Tracing CORT's Other Accumulated Expenses over 5 years: stood at $12.4 million in 2021, then grew by 17.13% to $14.6 million in 2022, then surged by 46.37% to $21.3 million in 2023, then soared by 58.78% to $33.9 million in 2024, then grew by 0.25% to $34.0 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CORT at $34.0 million in Q4 2025, $28.3 million in Q3 2025, and $29.0 million in Q2 2025.